Clopidogrel

Limits on what this shows

• Key negative or null findings: No human study measuring a mitochondrial function biomarker (e.g., blood lactate/pyruvate ratio, muscle biopsy respirometry) in clopidogrel-treated patients was located in this review, so there is no human null result to report either, only an absence of human data in either direction.
• At-risk subgroups: Not established for clopidogrel specifically. Idiosyncratic clopidogrel-associated hepatotoxicity is a recognized, rare clinical event, which is the population the Zahno et al. mechanism paper appears to be addressing, but this dossier did not verify whether that paper's proposed mechanism is mitochondrial versus another injury pathway (e.g., reactive metabolite-protein adduct formation, immune-mediated).

Regulatory status

Not addressed in the label. The label's Boxed Warning and Warnings sections cover CYP2C19 poor-metabolizer status and bleeding risk; no mitochondrial toxicity signal is listed.

Population evidence

Tier B only, in vitro/animal, no human data located. Tai et al. (2008, International Journal of Cardiology ) treated isolated mouse liver mitochondria with clopidogrel at 10 microg/mL and reported a significant reduction in mitochondrial respiration function. A second paper, Zahno et al. (2013, Free Radical Biology and Medicine ), is titled "Hepatocellular toxicity of clopidogrel: mechanisms and risk factors" and, per its title and venue, addresses mechanisms of clopidogrel-associated liver cell injury; this dossier could not independently verify its full abstract or methods beyond the search-listing title, journal, and year, so no specific statistic from it is asserted here beyond noting it as a second Tier B mechanistic source pointing at the same organ and concentration-dependent toxicity question.

Mechanism

Present, mechanism class E (mitochondrial interference). The reported effect is a direct reduction in isolated-mitochondria respiratory capacity at a concentration (10 microg/mL) that is far above typical human therapeutic plasma exposure; clopidogrel plasma concentrations in normal dosing are reported in the nanogram-per-mL range for the parent compound and lower still for the active thiol metabolite, which also has a roughly 30-minute half-life. Whether any dose-proportional, lower-magnitude effect exists at clinically achieved concentrations was not addressed by the retrieved study.

Counter-evidence held on record

The supporting finding is a single in vitro study on isolated animal organelles at a concentration this dossier could not confirm is clinically relevant; no independent replication, no human data, and no dose-response curve down to therapeutic concentrations were located. Per hard rule 3, an effect that has only been shown at a supraphysiologic concentration is not the same claim as an effect at labeled dosing, and this entry does not assert the latter. Framing caution for the consumer-facing surface Present this as "a laboratory finding at a concentration far above normal dosing, not a demonstrated effect in patients," never as "clopidogrel damages your mitochondria." No supplement (CoQ10 or otherwise) should be suggested at this grade; no consumer claim to that effect was found circulating for clopidogrel specifically (see claim audit below).

Limits on what this shows

• Key negative or null findings: The Ramadan et al. null result is itself the key negative finding: a Tier A human study in the same population this drug is actually used in (stable coronary artery disease) found no measurable change in oxidative stress markers with clopidogrel therapy.
• At-risk subgroups: None established in the harmful direction. If anything, the retrieved evidence suggests patients with type 2 diabetes and possibly peripheral arterial disease show a favorable oxidative-marker response, per titles alone; this dossier does not extend that into a therapeutic claim.

Regulatory status

Not addressed in the label; oxidative stress markers are not a labeled monitoring parameter for clopidogrel.

Population evidence

Tier A, human, direction protective-to-null. Ramadan et al. (2014, Journal of Cardiovascular Pharmacology ) studied clopidogrel therapy's effect on oxidative stress, inflammation, vascular function, and progenitor cells in stable coronary artery disease and, per the retrieved abstract snippet, found "no effect on endothelial function, arterial stiffness, inflammatory and oxidative stress markers," a null result. Taher and Nassir (2011, Saudi Pharmacy Journal ) studied clopidogrel in patients with type 2 diabetes and reported, per its title, "beneficial effects of clopidogrel on glycemic indices and oxidative stress," a protective-direction result. A third paper, Fakhri and Al-Ani (2024, Doklady Biochemistry and Biophysics ), titled "Superoxide Dismutase and Clopidogrel: A Potential Role in Peripheral Arterial Disease Treatment," examined clopidogrel's effect on oxidative stress in PAD patients; this dossier could not independently verify whether its cohort was human or animal, or its quantitative findings, beyond the search-listing title and is not load-bearing here beyond noting its existence. None of these three sources' full text was independently opened past the search-listing snippet; each is flagged accordingly in the sources list.

Mechanism

No harmful mechanism established at therapeutic dosing. P2Y12 receptor blockade reduces ADP-driven platelet activation, and activated platelets are a recognized endogenous source of reactive oxygen species; reducing platelet activation is therefore mechanistically consistent with a null-to-reduced oxidative-stress signal, which is the direction the two Tier A human studies actually show. The only harmful-direction mechanism found, hepatocyte injury possibly involving reactive oxygen species (Zahno et al. 2013), was reported at a supraphysiologic in vitro concentration, not at therapeutic human exposure, and concerns rare idiosyncratic hepatotoxicity rather than a population-wide depletion effect.

Counter-evidence held on record

This entry exists mainly to document that the harmful direction (clopidogrel increasing oxidative stress or depleting an antioxidant defense) is not what the retrieved human evidence shows. Graded yellow rather than left ungraded only because a real, if supraphysiologic, harmful-direction mechanism paper exists (Zahno et al. 2013) and because the human evidence, while reassuring, was not independently re-opened past its abstract snippet. Framing caution for the consumer-facing surface Do not present clopidogrel as depleting antioxidant status; the directly relevant human evidence points the other way. Do not present it as an antioxidant therapy either; the null result (Ramadan et al.) is the more cautious reading of a small, mixed evidence base.

Limits on what this shows

• Key negative or null findings: The DAPT anemia/iron-deficiency comparison above was null after adjustment (clopidogrel-based DAPT was not worse than ticagrelor- or prasugrel-based DAPT). A separate retrospective cohort of the same three DAPT regimens (n=1,327 recruited 2015-2016) likewise found no between-group difference in major GI bleeding (HR 0.996, 95% CI 0.497-1.996; 3.5% clopidogrel vs 3.3% newer agents), and an initial gap in minor GI complications (31.7% vs 19.7%) disappeared after adjustment. Both are active-comparator designs (P2Y12 inhibitor vs P2Y12 inhibitor, all with aspirin on board) and so cannot show whether clopidogrel-based DAPT differs from no antiplatelet therapy at all; that comparison was not found in the literature reviewed.
• At-risk subgroups: Older age, prior peptic ulcer disease or GI bleeding, concomitant NSAID or anticoagulant use, and DAPT (rather than clopidogrel alone) are the subgroups the retrieved bleeding literature actually flags as elevating GI bleeding risk; none of the retrieved sources stratified iron-deficiency risk specifically within these subgroups for clopidogrel.

Regulatory status

Label lists GI hemorrhage and bleeding broadly as adverse reactions (CAPRIE: 2.0% clopidogrel vs 2.7% aspirin GI hemorrhage; CURE: 3.7% clopidogrel+aspirin vs 2.7% placebo+aspirin major bleeding). The label documents bleeding as a clinical outcome; it does not report iron-deficiency or anemia rates as a nutrient-status finding.

Population evidence

Tier A, class-level bleeding, not iron-specific: a French national-database prospective cohort (SNIIRAM linkage, 2013-2015, n=69,911 new antiplatelet users, 63,600 monotherapy including a distinguishable clopidogrel arm) found major bleeding (including GI bleeds) was roughly twice as frequent with DAPT as with any monotherapy; it measured bleeding events, not iron indices. Tier A, DAPT-only, active comparator: a retrospective PCI cohort (n=1,327; 717 clopidogrel-based DAPT, 506 ticagrelor-based, 104 prasugrel-based, 12-month follow-up) defined "minor GI events" to include anemia (hemoglobin under sex-specific thresholds with iron deficiency) and iron deficiency alone (ferritin under 30 ng/mL, transferrin saturation under 19%); 31.7% of the clopidogrel-DAPT group met this composite versus 19.7% of the newer-agent group, but the difference did not survive adjustment for confounders (HR 0.920, 95% CI 0.712-1.189). Every arm in this study also received aspirin, so it cannot separate a clopidogrel-specific iron effect from aspirin's own, better-documented direct mucosal-injury effect.

Mechanism

Present, but distinct from aspirin's mechanism (mechanism class F, GI absorption/blood-loss pathway). Clopidogrel does not directly injure gastric mucosa; it impairs platelet aggregation via irreversible P2Y12 antagonism, which can prevent normal hemostatic sealing of pre-existing mucosal lesions and prolong bleeding from any GI source. A prospective endoscopic study (single center, n=172: 108 aspirin-monotherapy, 46 clopidogrel-monotherapy, 18 DAPT) supports this distinction directly: modified Lanza mucosal-injury scores were lowest with clopidogrel alone (0.72 +/- 1.29), higher with aspirin alone (0.95 +/- 1.61), and highest with DAPT (1.67 +/- 1.81, p=0.03 vs clopidogrel alone), consistent with the authors' interpretation that clopidogrel itself does not cause direct mucosal injury but can prolong bleeding from lesions aspirin (or other causes) already created.

Counter-evidence held on record

Two DAPT-vs-DAPT active-comparator studies found no clopidogrel-specific excess in either major GI bleeding or the anemia/iron-deficiency composite once other P2Y12 inhibitors were used as the comparator. No study reviewed compared clopidogrel monotherapy iron status against an untreated or non-antiplatelet population, so the direction of any true monotherapy-specific effect remains unmeasured, not merely unconfirmed. Framing caution for the consumer-facing surface Present this as "worth watching if you have other bleeding risk factors," never as "clopidogrel depletes iron." The GI hemorrhage numbers in clopidogrel's own label are a bleeding-event rate, not an iron-deficiency rate, and must never be re-labeled as the latter. No supplemental iron dose should be suggested at this grade.

Limits on what this shows

• Why no grade: Per this dossier's governance key, UNGRADED applies only when both conditions hold: no Tier B/C mechanistic or class-level evidence exists, and no circulating consumer claim exists to rebut. A PubMed search for clopidogrel and copper returned only unrelated results (copper used as a laboratory oxidation reagent, copper catalysis in clopidogrel's chemical synthesis, and a coronary-vasospasm inflammatory-marker study that mentions clopidogrel treatment without measuring copper). No study measuring ceruloplasmin, serum copper, or any copper-dependent enzyme activity in clopidogrel-treated patients or animals was located. No consumer drug-interaction or supplement-depletion source raising a clopidogrel/copper claim was found either. Both conditions for UNGRADED are met.
• What would fill it: Any Tier B or Tier C source (an in vitro, animal, or class-level P2Y12-inhibitor study measuring copper status or a copper-dependent enzyme) would move this to yellow. A Tier A human study measuring serum copper or ceruloplasmin in clopidogrel-treated patients against a control would be needed to reach orange or above.

Regulatory status

Not addressed in the label.

Limits on what this shows

• Why no grade: A targeted search for clopidogrel, iron absorption, and hepcidin returned zero results. This is a different question from the existing bleeding-mediated iron entry above, which does have Tier A-adjacent evidence (bounded, DAPT-confounded) and remains unchanged; this entry exists only to record that the non-bleeding pathway was checked for and found empty, so the absence is not mistaken for reassurance about iron overall.
• What would fill it: Any study measuring intestinal iron absorption, hepcidin, or an iron transporter in clopidogrel-exposed tissue or patients, independent of a bleeding/blood-loss pathway, would move this to yellow at minimum.

Regulatory status

Not addressed in the label.

Limits on what this shows

• Key negative or null findings: None located; no study comparing clopidogrel monotherapy, aspirin monotherapy, and untreated controls on gut flora composition was found in this review, so the DAPT-vs-monotherapy and DAPT-vs-no-antiplatelet comparisons both remain unmeasured.
• At-risk subgroups: Not established. The underlying cardiovascular or cerebrovascular disease that leads to a DAPT prescription, and any concomitant PPI or antibiotic use in this population, are plausible independent drivers of gut flora composition and were not excluded by the retrieved study.

Regulatory status

Not addressed in the label; gut microbiome composition is not a labeled monitoring parameter.

Population evidence

Tier A, human, but DAPT rather than clopidogrel-monotherapy. Chao et al. (2020, Journal of Drug Targeting ), "Study on the characteristic of intestinal flora in patients with dual antiplatelet therapy," reports that the clopidogrel-treated (DAPT) group showed a higher abundance of the genera Streptococcus and Klebsiella relative to its comparator. This dossier could not independently verify the full text (sample size, exact comparator group, or statistical significance) beyond the search-listing title, journal, year, and the genus-level snippet quoted above, and flags it accordingly in the sources list.

Mechanism

Present but unnamed by the retrieved source; mechanism class G (microbiome disruption) is plausible in general for a drug that alters mucosal bleeding and local hemostasis, and also plausible as a downstream effect of any GI mucosal change from aspirin (present in every arm of this study), rather than from clopidogrel's own P2Y12 mechanism. The retrieved snippet does not attribute a mechanism to clopidogrel specifically.

Counter-evidence held on record

Per hard rule 2 of this protocol (confounding by indication is presumed until actively considered), this finding is presumed confounded until a study isolates clopidogrel from aspirin, from the underlying cardiovascular indication, and from concomitant gastroprotective or antibiotic therapy. None of those isolations have been done in the literature located here. Framing caution for the consumer-facing surface Present as "an association seen in dual-therapy patients, not proven to be caused by clopidogrel itself," never as "clopidogrel disrupts your gut bacteria." No probiotic or supplement recommendation should be made at this grade.

Limits on what this shows

• Key negative or null findings: Not established in the sources located; both retrieved studies report a positive (microbiome-affects-drug) association rather than a null result.
• At-risk subgroups: Patients on antibiotics, or at high altitude, while also taking clopidogrel, per the two retrieved study contexts; whether either translates to a clinically meaningful change in antiplatelet effect in humans was not established by either source as retrieved.

Regulatory status

Not addressed in the label.

Population evidence

Zhang et al. (2023, Current Drug Metabolism ), "Comprehensive Investigation of the Influence of High-Altitude Hypoxia on Clopidogrel Metabolism and Gut Microbiota," and Chen et al. (2022, Drug Metabolism and Disposition ), "Antibiotics-induced disruption of gut microbiota increases systemic exposure of clopidogrel active metabolite in type 2 diabetic rats." Both are Tier B or mixed Tier A/B (species and human-vs-animal status not independently confirmed for the Zhang paper beyond its title and search-listing snippet); neither was opened past the search-listing summary, and both are flagged in the sources list accordingly.

Mechanism

Gut bacterial composition affecting either clopidogrel's absorption or its conversion to the active thiol metabolite, the reverse of a microbiome-harm question. This is a drug-affected-by-microbiome relationship, not clopidogrel affecting microbiome health, and per hard rule 4 of this protocol it is filed as a direction note, not forced into the gut-microbiome-risk tier above.

Counter-evidence held on record

Neither retrieved source was opened past its search-listing summary, so the magnitude and clinical significance of either effect could not be independently confirmed; this entry records the existence and direction of the finding only, consistent with the citation-integrity flag used elsewhere in this dossier for sources that could not be fully verified. Framing caution for the consumer-facing surface This is not clopidogrel harming the gut microbiome, and it is not a nutrient-depletion claim. It is the gut microbiome potentially affecting how much active clopidogrel a patient's body produces. It belongs in cross-drug/cross-factor monitoring, never in a nutrient-deficiency list.

Limits on what this shows

• Key negative or null findings: None located specifically contradicting this result; no study reviewed here found clopidogrel worsening microvascular function or tissue oxygenation.
• At-risk subgroups: Not applicable; this is not a risk finding. The population studied was patients with stable coronary artery disease, the population in which clopidogrel is commonly used.

Regulatory status

Not addressed in the label as a nutrient or oxygen-delivery parameter; the label's own efficacy data (CAPRIE, CURE, CLARITY, COMMIT) describe reduced ischemic cardiovascular events, a different, already-labeled clinical outcome that this entry does not restate.

Population evidence

Tier A, human. Willoughby et al. (2014, Heart, Lung and Circulation ), "Clopidogrel improves microvascular endothelial function in subjects with stable coronary artery disease" (PMID 24529502), reported improved microvascular endothelial function with clopidogrel therapy. This dossier confirmed the study's conclusion via the search-listing snippet but could not independently open the full abstract for sample size or effect-size detail, and flags it accordingly in the sources list.

Mechanism

Present, and distinct from clopidogrel's core antiplatelet mechanism: reduced platelet activation lowers platelet-derived mediators (including some that impair endothelial nitric oxide signaling), which is mechanistically consistent with improved endothelium-dependent vasodilation and, by extension, microvascular blood flow and tissue oxygen delivery. This is a secondary vascular effect of the drug's intended antiplatelet action, not a nutrient effect, and per hard rule 1 of this protocol is not filed as a deficiency finding of any kind.

Counter-evidence held on record

This entry rests on a single Tier A study whose full text was not independently re-opened; it is graded yellow (context flag) rather than a higher tier both because of that verification gap and because, per hard rule 1, a drug's own intended or expected pharmacological benefit is not the kind of finding this dossier's tiers are built to escalate, regardless of direction. Framing caution for the consumer-facing surface Present as "clopidogrel's antiplatelet action may support small-vessel blood flow," never as evidence that clopidogrel corrects a nutrient-related oxygen-delivery deficiency; no nutrient is implicated in this mechanism.

Limits on what this shows

• Key negative or null findings: No human ATP or bioenergetic biomarker study in clopidogrel-treated patients was located in this review, so there is no human null result to report, only an absence of human data.
• At-risk subgroups: Not established for clopidogrel specifically.

Regulatory status

Not addressed in the label.

Population evidence

Tier B only, same single source as the mitochondrial burden entry: Tai et al. (2008, International Journal of Cardiology ), isolated mouse liver mitochondria, clopidogrel 10 microg/mL, significantly reduced respiration function in vitro. Two related human platelet-bioenergetics papers were also located, Arauna et al. (2024, Life Sciences ), on platelet mitochondrial calcium/metabolism in activation-related disease and aging, and Jávor et al. (2021, European Surgical Research ), on platelet mitochondrial oxidative-phosphorylation capacity in trauma-related coagulopathy; neither studied clopidogrel or any P2Y12 inhibitor, so both are background mechanism context establishing that platelet mitochondrial ATP output is a real, measurable, clinically relevant parameter in principle, not evidence for or against a clopidogrel effect on it.

Mechanism

Present, mechanism class E, identical mechanism to the mitochondrial burden entry: mitochondrial respiratory impairment necessarily reduces oxidative ATP yield. As with that entry, the only measured concentration (10 microg/mL) is far above typical human therapeutic plasma exposure, and no dose-response data closer to clinical exposure were located.

Counter-evidence held on record

This is the same evidentiary base as the mitochondrial burden entry above, one Tier B in vitro source at a supraphysiologic concentration, restated here as its direct functional implication (ATP output) rather than as a separate independent finding; see the overlap map below for how this dossier avoids double-counting the single underlying source. Framing caution for the consumer-facing surface Present as "a laboratory finding at a concentration far above normal dosing," never as "clopidogrel lowers your cellular energy." No CoQ10 or other energy-support supplement claim was found circulating for clopidogrel specifically (see claim audit below), and none should be suggested at this grade.